Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:NAMS NASDAQ:RGC NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$68.78-0.3%$71.29$31.77▼$84.94$13.51B1.022.59 million shs2.12 million shsNAMSNewAmsterdam Pharma$29.88+0.1%$31.90$16.78▼$42.00$3.43B0.02940,406 shs885,491 shsRGCRegencell Bioscience$27.27-0.3%$27.06$2.62▼$83.60$13.53B1.8899,949 shs66,271 shsSMMTSummit Therapeutics$17.54+3.3%$18.46$13.83▼$30.98$13.18B-1.254.96 million shs4.49 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.32%-1.39%-5.97%-8.53%+79.96%NAMSNewAmsterdam Pharma+5.10%+4.04%-9.42%-9.40%+47.63%RGCRegencell Bioscience-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%SMMTSummit Therapeutics+8.88%-17.50%-9.49%+21.55%-37.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$68.78-0.3%$71.29$31.77▼$84.94$13.51B1.022.59 million shs2.12 million shsNAMSNewAmsterdam Pharma$29.88+0.1%$31.90$16.78▼$42.00$3.43B0.02940,406 shs885,491 shsRGCRegencell Bioscience$27.27-0.3%$27.06$2.62▼$83.60$13.53B1.8899,949 shs66,271 shsSMMTSummit Therapeutics$17.54+3.3%$18.46$13.83▼$30.98$13.18B-1.254.96 million shs4.49 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.32%-1.39%-5.97%-8.53%+79.96%NAMSNewAmsterdam Pharma+5.10%+4.04%-9.42%-9.40%+47.63%RGCRegencell Bioscience-6.35%-6.13%-11.46%-3.91%+2,726,999,900.00%SMMTSummit Therapeutics+8.88%-17.50%-9.49%+21.55%-37.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.92Moderate Buy$87.7127.53% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.0060.64% UpsideRGCRegencell Bioscience 1.00SellN/AN/ASMMTSummit Therapeutics 2.59Moderate Buy$27.5857.26% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, SMMT, RGC, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $23.005/1/2026SMMTSummit Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $16.004/29/2026BBIOBridgeBio Pharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$95.00 ➝ $102.004/28/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$106.004/27/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.004/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SMMTSummit Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026BBIOBridgeBio Pharma Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$100.004/8/2026SMMTSummit Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/8/2026BBIOBridgeBio Pharma Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy4/8/2026SMMTSummit Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$502.08M26.82N/AN/A($10.77) per share-6.39NAMSNewAmsterdam Pharma$22.50M152.69N/AN/A$5.97 per share5.01RGCRegencell BioscienceN/AN/AN/AN/A$0.01 per shareN/ASMMTSummit TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$724.93M-$3.78N/A146.34N/A-144.39%N/A-74.43%5/7/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.73N/AN/AN/A-906.22%-26.67%-24.82%5/7/2026 (Estimated)RGCRegencell Bioscience-$3.58MN/AN/AN/AN/AN/AN/AN/AN/ASMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%N/ALatest NAMS, SMMT, RGC, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70N/AN/AN/A$178.64 millionN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46N/AN/AN/A$1.09 millionN/A4/30/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A2/24/2026Q4 2025BBIOBridgeBio Pharma-$0.75-$1.00-$0.25-$1.00$150.71 million$154.18 million2/23/2026Q4 2025SMMTSummit Therapeutics-$0.22-$0.29-$0.07-$0.29$75.47 millionN/A2/18/2026Q4 2025NAMSNewAmsterdam Pharma-$0.40-$0.63-$0.23-$0.63$0.92 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ARGCRegencell BioscienceN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A2.772.68NAMSNewAmsterdam PharmaN/A7.887.88RGCRegencell BioscienceN/AN/AN/ASMMTSummit TherapeuticsN/A7.419.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%NAMSNewAmsterdam Pharma89.89%RGCRegencell Bioscience0.13%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma14.23%NAMSNewAmsterdam Pharma20.84%RGCRegencell BioscienceN/ASMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400195.81 million167.94 millionOptionableNAMSNewAmsterdam Pharma4114.97 million91.01 millionOptionableRGCRegencell Bioscience10494.49 millionN/AN/ASMMTSummit Therapeutics110776.16 million128.05 millionOptionableNAMS, SMMT, RGC, and BBIO HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Given New $23.00 Price Target at HC WainwrightMay 5 at 3:27 AM | americanbankingnews.comSMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackMay 4 at 2:15 PM | zacks.comSummit Therapeutics: More Uncertainty Heading Into The ASCO PlenaryMay 4 at 12:33 PM | seekingalpha.comBuy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash RunwaysMay 4 at 11:07 AM | 247wallst.comSummit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 4 at 9:23 AM | globenewswire.comHC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock PriceMay 4 at 8:22 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)May 3 at 2:56 PM | theglobeandmail.comSummit Therapeutics (SMMT) Receives a Rating Update from a Top AnalystMay 3 at 2:56 PM | theglobeandmail.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - What's Next?May 3 at 3:53 AM | americanbankingnews.comSMMT stock plunges on wider Q1 loss, lung cancer clinical trial updateMay 2, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsMay 2, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street ZenMay 2, 2026 | marketbeat.comSummit Therapeutics Shock Move Hits Nasdaq FuturesMay 1, 2026 | kalkinemedia.comKSummit Therapeutics falls after update on Akeso-partnered lung cancer trialMay 1, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?May 1, 2026 | marketbeat.comSummit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026April 30, 2026 | businesswire.comSummit Therapeutics: It Still Feels Like The Market Got Ahead Of ItselfApril 30, 2026 | seekingalpha.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 30, 2026 | americanbankingnews.comSummit Therapeutics (SMMT) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comSummit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growthApril 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, SMMT, RGC, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$68.78 -0.21 (-0.30%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$69.12 +0.34 (+0.50%) As of 05/5/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.NewAmsterdam Pharma NASDAQ:NAMS$29.88 +0.02 (+0.07%) Closing price 05/5/2026 03:59 PM EasternExtended Trading$30.36 +0.47 (+1.59%) As of 05/5/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Regencell Bioscience NASDAQ:RGC$27.27 -0.09 (-0.33%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$27.84 +0.57 (+2.09%) As of 05/5/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.Summit Therapeutics NASDAQ:SMMT$17.54 +0.56 (+3.30%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$17.47 -0.07 (-0.40%) As of 05/5/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
